Pulmonary Sequelae of COVID-19: Focus on Interstitial Lung Disease

Author:

Johnston Janet1,Dorrian Delia2,Linden Dermot23,Stanel Stefan Cristian14,Rivera-Ortega Pilar1ORCID,Chaudhuri Nazia5ORCID

Affiliation:

1. Interstitial Lung Diseases Unit, North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK

2. Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast BT9 7BL, UK

3. Mater Hospital, Belfast Health and Social Care Trust, Belfast BT14 6AB, UK

4. Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK

5. School of Medicine, Magee Campus, University of Ulster, Northlands Road, Londonderry BT48 7JL, UK

Abstract

As the world transitions from the acute phase of the COVID-19 pandemic, a novel concern has arisen—interstitial lung disease (ILD) as a consequence of SARS-CoV-2 infection. This review discusses what we have learned about its epidemiology, radiological, and pulmonary function findings, risk factors, and possible management strategies. Notably, the prevailing radiological pattern observed is organising pneumonia, with ground-glass opacities and reticulation frequently reported. Longitudinal studies reveal a complex trajectory, with some demonstrating improvement in lung function and radiographic abnormalities over time, whereas others show more static fibrotic changes. Age, disease severity, and male sex are emerging as risk factors for residual lung abnormalities. The intricate relationship between post-COVID ILD and idiopathic pulmonary fibrosis (IPF) genetics underscores the need for further research and elucidation of shared pathways. As this new disease entity unfolds, continued research is vital to guide clinical decision making and improve outcomes for patients with post-COVID ILD.

Publisher

MDPI AG

Subject

General Medicine

Reference84 articles.

1. (2023, March 07). Listing of WHO’s Response to COVID-19. Available online: https://www.who.int/news/item/29-06-2020-covidtimeline.

2. Characteristics of SARS-CoV-2 and COVID-19;Hu;Nat. Rev. Microbiol.,2021

3. (2023, March 07). WHO Coronavirus (COVID-19) Dashboard with Vaccination Data. Available online: https://covid19.who.int/.

4. World Health Organization (2023, March 07). Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected: Interim Guidance. Available online: https://www.who.int/publications/i/item/10665-332299.

5. RECOVERY Collaborative Group, Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., and Ustianowski, A. (2021). Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med., 384, 693–704.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3